참고문헌
- Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In : Scriver CR, Beaudet AL, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York : McGraw-Hill company, 2001: 3257-301
- Moser HW, Fatemi A, Zackowski K, Smith S, Golay X, Muenz L, et al. Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 2004;29:1003-16 https://doi.org/10.1023/B:NERE.0000021245.12181.90
- Rizzo WB, Leshner RT, Odone A, Damman AL, Craft DA, Jensone ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22 https://doi.org/10.1212/WNL.39.11.1415
- Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9 https://doi.org/10.1159/000112173
- Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, et al. Adrenoleukodystrophy : phenotypic variability and implications for therapy. J Inher Metab Dis 1992;15:645-64 https://doi.org/10.1007/BF01799621
- Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, et al. A two-year trial of oleic acid and erucic acids('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329:745-52. https://doi.org/10.1056/NEJM199309093291101
- Asano J, Sujuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994;16:454-8 https://doi.org/10.1016/0387-7604(94)90007-8
- Korenke GC, Hunneman DH, Kohler J, StOckler S, Landmark K, Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/ adrenomyeloneuropathy : effect on clinical, biochemical, and neurophysiological parameters. Eur J Pediatr 1995; 154:64-70 https://doi.org/10.1007/BF01972976
- Moser HW, Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995;15:379-97 https://doi.org/10.1146/annurev.nu.15.070195.002115
- Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with 'Lorenzo's oil'. J Neurol Neurosurg Psychiat 1999;67: 290-9 https://doi.org/10.1136/jnnp.67.3.290
- Brown FR 3rd, van Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, et al. Adrenoleukodystrophy : effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982;151: 164-72
- Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy : oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 1986;36:357- 61 https://doi.org/10.1212/WNL.36.3.357
- Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, et al. Adrenoleukodystrophy : dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21: 232-9 https://doi.org/10.1002/ana.410210304
- Odone A, Odone M. Lorenzo's oil : a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989;5:55-61 https://doi.org/10.4103/1817-1745.66681
- Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-5 https://doi.org/10.1097/00005072-199509000-00017
- Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleu-kodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6. https://doi.org/10.1002/ana.410360509
- Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adrenoleukodystrophy : cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-43 https://doi.org/10.1097/00005072-199211000-00007
- Bourre JM, Daudu O, Baumann N. Nervonic acid biosynthesis by erucyl-coA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-coAs(mono and polyunsaturated). Biochim Biophys Acta 1976;424:1-7 https://doi.org/10.1016/0005-2760(76)90043-6
- Janet B, Jannifer C. ALD-AMN diet cookbook. Sycamore : United Leukodystrophy Foundation, 1990:1-20
- Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:1860-6 https://doi.org/10.1056/NEJM199006283222607
- Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76 https://doi.org/10.1097/00019052-199904000-00007
- Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000;356:713-8 https://doi.org/10.1016/S0140-6736(00)02629-5
- Singh I, Pahan K, Kahn M. Lovastatin and sodium phenylacetate normalize the levels of very-long-chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 1998;426:342-6 https://doi.org/10.1016/S0014-5793(98)00370-6
- Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999;269:71-4 https://doi.org/10.1016/S0304-3940(99)00414-0
- Weinhofer I, Forss-Petter S, Zigman M, Berger J. Cholesterol regulates ABCD2 expression : implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 2002;11:2701-8 https://doi.org/10.1093/hmg/11.22.2701
- Koc ON, Day J, Nieder M, Gerson SL, Luzarus HM, Krivit W. Allogenic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome( MPS-IH). Bone Marrow Transplant 2002;30:215-22. https://doi.org/10.1038/sj.bmt.1703650